A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body
This research study is for people who have chronic kidney disease, which means their kidneys aren't working as well as they should over a long time. We're testing a new tablet called nurandociguat. The main goal is to understand exactly how the body absorbs this new tablet and processes it, compared to an older version of the same medicine. We also want to see if eating food at the same time as taking the new tablet changes how the body takes it in. This is a very early stage study, focused on understanding how the medicine works in the body.
At a glance
What is this study about?
This study is all about a new tablet called nurandociguat, designed for people living with chronic kidney disease. Chronic kidney disease is a long-term condition where the kidneys don't filter blood as well as they should, which can lead to various health problems. Developing new and better treatments is an ongoing process.
In this particular study, we're trying to understand two main things. Firstly, how does the body take in and use this new nurandociguat tablet? This is really important to know how effective a medicine might be. We'll be comparing it to an older version of the tablet to see if there are any differences. Secondly, we want to figure out if eating food around the same time you take the new tablet changes how much of the medicine your body absorbs and how it processes it. Sometimes, food can make a big difference to how well a medicine works or if it causes side effects.
This is what's called a 'Phase I' study, which means it's one of the first times this new tablet is being carefully studied in people. The main aim at this stage isn't to see if it cures the disease, but rather to learn how it behaves inside the human body. This basic information is crucial for developing the medicine further and ensuring it can eventually be used safely and effectively by more people if it proves helpful.
Key takeaways
- This study is testing a new tablet for chronic kidney disease.
- It aims to understand how the body absorbs and uses the new medicine.
- It will compare the new tablet to an older version.
- Researchers will also check if food affects how the new tablet works.
- This is an early-stage study (Phase I) focused on understanding the drug's behaviour in the body.
- Participants must be 18 or older and have chronic kidney disease.
Who may be eligible?
To be able to join this study, participants must be at least 18 years old. There is no upper age limit, meaning older adults are welcome to take part too.
Participants also need to have been diagnosed with chronic kidney disease. This study is open to both men and women.
Specific medical conditions or medications might prevent someone from joining, even if they meet the general age and kidney disease criteria. This is to ensure the safety of everyone taking part and the accuracy of the study results.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years or older?
- Do you have a diagnosis of chronic kidney disease?
- Are you able to attend several clinic visits?
- Are you comfortable with regular blood tests?
What does participation involve?
Taking part in this study would involve several visits to a clinic. During these visits, you would have blood samples taken regularly to measure how much of the study drug is in your system. We might also collect urine samples. You would be given the study medication, nurandociguat, either the new tablet or the older version, and sometimes with food, sometimes without, as directed by the study team. Doctors and nurses would regularly check your health and any side effects you might experience. The total duration of your participation would involve a number of clinic visits and follow-up, but the exact schedule and length would be explained in detail before you agree to take part.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is nurandociguat?
Nurandociguat is a new medicine being developed to help people with chronic kidney disease.
Why do you need to know about food?
Sometimes, eating food at the same time as taking a medicine can change how your body takes it in, which is important for safety and how well it works.
Is this a new treatment for my kidney disease?
This is an early study to understand how the medicine works in the body; it's not yet known if it will be a new treatment for your condition.
How long will I be in the study?
The exact length of the study for each participant will be explained by the study team, as it can vary, but involves multiple visits.
Will I get paid for taking part?
Information about any potential compensation for your time and travel will be provided by the study team.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.